Full Publication List


  1. PKM2 rewires glucose metabolism during radiation therapy to promote an antioxidant response and glioblastoma radioresistance. 
    Bailleul J, Ruan Y, Abdulrahman L, Scott AJ, Yazal T, Sung D, Park K, Hoang H, Nathaniel J, Chu FI, Palomera D, Sehgal A, Tsang JE, Nathanson DA, Xu S, Park JO, ten Hoeve J, Bhat K, Gi N, Kornblum HI, Schaue D, McBride WH, Lyssiotis CA, Wahl DR, Vlashi E.
    Neuro-Oncol. 2023 Jun 5. Online ahead of print. PubMed

  2. Glioblastomas: Hijacking Metabolism to Build a Flexible Shield for Therapy Resistance. 
    Bailleul J,  Vlashi E.
    Antioxid Redox Signal. 2023 Apr 5. Epub ahead of print. PubMed

  3. NRF2 mediates cellular resistance to transformation, radiation, and inflammation in mice. 
    Schaue D, Micewizc ED, Ratikan JA, Iwamoto KS, Vlashi E, McDonald JT, McBride WH.
    Antioxidants (Basel). 2022 Aug 25;11(9):1649. PubMed

  4. Metabolic response to radiation therapy in cancer.
    Read GH, Bailleul J, Vlashi E, Kesarwala AH.
    Mol Carcinog. 2022 Feb;61(2):200-224. PubMed

  5. Radiosensitizing pancreatic cancer via effective autophagy inhibition.
    Yazal T, Bailleul J, Ruan Y, Sung D, Chu FI, Palomera D, Dao A, Sehgal A, Gurunathan V, Aryan L, Eghbali M, Vlashi E.
    Mol Cancer Ther. 2022 Jan;21(1):79-88. PubMed

  6. Three discipline collaborative radiation therapy (3DCRT) special debate: Peer review in radiation oncology is more effective today than 20 years ago.
    Ahmad A, Santanam L, Solanki AA, Padilla L, Vlashi E, Guerrieri P, Dominello MM, Burmeister J, Joiner MC.
    J Appl Clin Med Phys. 2020 Nov;21(11):7-13. PubMed

  7. The dopamine receptor antagonist trifluoperazine prevents phenotype conversion and improves survival in mouse models of glioblastoma.
    Bhat K, Saki M, Vlashi E, Cheng F, Duhachek-Muggy S, Alli C, Yu G, Medina P, He L, Damoiseaux R, Pellegrini M, Zemke NR, Nghiemphu PL, Cloughesy TF, Liau LM, Kornblum HI, Pajonk F.
    Proc Natl Acad Sci U S A. 2020 May 19;117(20):11085-11096. PubMed

  8. Radiation mitigation of the intestinal acute radiation injury in mice by 1-[(4-nitrophenyl)sulfonyl]-4-phenylpiperazine.
    Duhachek-Muggy S, Bhat K, Medina P, Cheng F, He L, Alli C, Saki M, Muthukrishnan SD, Ruffenach G, Eghbali M, Vlashi E, Pajonk F.
    Stem Cells Transl Med. 2020 Jan;9(1):106-119. PubMed

  9. PK-M2-mediated metabolic changes in breast cancer cells induced by ionizing radiation.
    Zhang L, Bailleul J, Yazal T, Dong K, Sung D, Dao A, Gosa L, Nathanson D, Bhat K, Duhachek-Muggy S, Alli C, Dratver MB, Pajonk F, Vlashi E.
    Breast Cancer Res Treat. 2019 Nov;178(1):75-86. PubMed

  10. The KRAS-variant and its impact on normal breast epithelial cell biology.
    Jung SY, Malhotra P, Nguyen KC, Salzman D, Qi Y, Pak EH, King J, Vlashi E, Ann D, Weidhaas JB.
    Cell Death Differ. 2019 Dec;26(12):2568-2576. PubMed

  11. 1-(4-nitrobenzenesulfonyl)-4-penylpiperazine increases the number of Peyer's patch-associated regenerating crypts in the small intestines after radiation injury.
    Bhat K, Duhachek-Muggy S, Ramanathan R, Saki M, Alli C, Medina P, Damoiseaux R, Whitelegge J, McBride WH, Schaue D, Vlashi E, Pajonk F.
    Radiother Oncol. 2019 Mar;132:8-15. PubMed

  12. Three discipline collaborative radiation therapy (3DCRT) special debate: I would treat all early-stage NSCLC patients with SBRT.
    Mohindra P, Sawant A, Griffin RJ, Lamichhane N, Vlashi E, Xu-Welliver M, Dominello M, Joiner MC, Burmeister J.
    J Appl Clin Med Phys. 2019 Mar;20(3):7-13. PubMed

  13. Serum erythropoietin levels, breast cancer and breast cancer-initiating cells.
    Bhat K, Sandler K, Duhachek-Muggy S, Alli C, Cheng F, Moatamed NA, Magyar CE, Du L, Li G, McCloskey S, Vlashi E, Pajonk F.
    Breast Cancer Res. 2019 Jan 30;21(1):17. PubMed

  14. If It Seems Too Good to Be True...
    Steinberg ML, McBride WH, Vlashi E, Pajonk F.
    Int J Radiat Oncol Biol Phys. 2019 Feb 1;103(2):305-307. PubMed

  15. Mebendazole Potentiates Radiation Therapy in Triple-Negative Breast Cancer.
    Zhang L, Bochkur Dratver M, Yazal T, Dong K, Nguyen A, Yu G, Dao A, Bochkur Dratver M, Duhachek-Muggy S, Bhat K, Alli C, Pajonk F, Vlashi E.
    Int J Radiat Oncol Biol Phys. 2019 Jan 1;103(1):195-207. PubMed

  16. Doxycycline inhibits the cancer stem cell phenotype and epithelial-to-mesenchymal transition in breast cancer.
    Zhang L, Xu L, Zhang F, Vlashi E.
    Cell cycle. 2017 Apr 18;16(8):737-45. PubMed

  17. Growth Differentiation Factor 11 does not Mitigate the Lethal Effects of Total-Abdominal Irradiation.
    Duhachek-Muggy S, Bhat K, Vlashi E, Pajonk F.
    Radiation research. 2017 Nov;188(5):469-75. PubMed

  18. Radiation-Induced Dedifferentiation of Head and Neck Cancer Cells Into Cancer Stem Cells Depends on Human Papillomavirus Status.
    Vlashi E, Chen AM, Boyrie S, Yu G, Nguyen A, Brower PA, Hess CB, Pajonk F.
    International journal of radiation oncology, biology, physics. 2016 Apr 01;94(5):1198-206. PubMed

  19. Cancer stem cells, cancer cell plasticity and radiation therapy.
    Vlashi E, Pajonk F.
    Seminars in cancer biology. 2015 Apr;31:28-35. PubMed

  20. The metabolic state of cancer stem cells-a valid target for cancer therapy?
    Vlashi E, Pajonk F.
    Free radical biology & medicine. 2015 Feb;79:264-8. PubMed

  21. Metabolic differences in breast cancer stem cells and differentiated progeny.
    Vlashi E, Lagadec C, Vergnes L, Reue K, Frohnen P, Chan M, Alhiyari Y, Dratver MB, Pajonk F.
    Breast cancer research and treatment. 2014 Aug;146(3):525-34. PubMed

  22. Folate Receptor-beta in Activated Macrophages: Ligand Binding and Receptor Recycling Kinetics.
    Varghese B, Vlashi E, Xia W, Ayala Lopez W, Paulos CM, Reddy J, Xu LC, Low PS.
    Molecular pharmaceutics. 2014 Oct 6;11(10):3609-16. PubMed

  23. The RNA-binding protein Musashi-1 regulates proteasome subunit expression in breast cancer- and glioma-initiating cells.
    Lagadec C, Vlashi E, Frohnen P, Alhiyari Y, Chan M, Pajonk F.
    Stem Cells. 2014 Jan;32(1):135-44. PubMed

  24. Tumor cells with low proteasome subunit expression predict overall survival in head and neck cancer patients.
    Lagadec C, Vlashi E, Bhuta S, Lai C, Mischel P, Werner M, Henke M, Pajonk F.
    BMC cancer. 2014;14:152. PubMed

  25. Targeted elimination of breast cancer cells with low proteasome activity is sufficient for tumor regression.
    Vlashi E, Lagadec C, Chan M, Frohnen P, McDonald AJ, Pajonk F.
    Breast cancer research and treatment. 2013 Sep;141(2):197-203. PubMed

  26. Effect of folate-targeted nanoparticle size on their rates of penetration into solid tumors.
    Vlashi E, Kelderhouse LE, Sturgis JE, Low PS.
    ACS nano. 2013 Oct 22;7(10):8573-82. PubMed

  27. National Institutes of Health funding in radiation oncology: a snapshot.
    Steinberg M, McBride WH, Vlashi E, Pajonk F.
    International journal of radiation oncology, biology, physics. 2013 Jun 1;86(2):234-40. PubMed

  28. Characterization of the stem cell niche and its importance in radiobiological response.
    Pajonk F, Vlashi E.
    Seminars in radiation oncology. 2013 Oct;23(4):237-41. PubMed

  29. Radiation-Induced Notch Signaling in Breast Cancer Stem Cells.
    Lagadec C, Vlashi E, Alhiyari Y, Phillips TM, Dratver MB, Pajonk F.
    International journal of radiation oncology, biology, physics. 2013 Aug 27. PubMed

  30. Folate-linked drugs for the treatment of cancer and inflammatory diseases.
    Yang J, Vlashi E, Low P.
    Sub-cellular biochemistry. 2012;56:163-79. PubMed

  31. Radiation-induced reprogramming of breast cancer cells.
    Lagadec C, Vlashi E, Della Donna L, Dekmezian C, Pajonk F.
    Stem cells. 2012 May;30(5):833-44. PubMed

  32. Metabolic state of glioma stem cells and nontumorigenic cells.
    Vlashi E, Lagadec C, Vergnes L, Matsutani T, Masui K, Poulou M, Popescu R, Della Donna L, Evers P, Dekmezian C, Reue K, Christofk H, Mischel PS, Pajonk F.
    Proceedings of the National Academy of Sciences of the United States of America: PNAS. 2011 PubMed

  33. Targeted cancer stem cell therapies start with proper identification of the target.
    Vlashi E, Pajonk F.
    Molecular cancer research: MCR. 2010 Feb;8(2):291. PubMed

  34. Differential Effects of the Proteasome Inhibitor NPI-0052 against Glioma Cells.
    Vlashi E, Mattes M, Lagadec C, Donna LD, Phillips TM, Nikolay P, McBride WH, Pajonk F.
    Translational oncology. 2010 Feb;3(1):50-5. PubMed

  35. Radiation resistance of cancer stem cells: the 4 R's of radiobiology revisited.
    Pajonk F, Vlashi E, McBride WH.
    Stem cells. 2010 Apr;28(4):639-48. PubMed

  36. Ionizing radiation activates the Nrf2 antioxidant response.
    McDonald JT, Kim K, Norris AJ, Vlashi E, Phillips TM, Lagadec C, Della Donna L, Ratikan J, Szelag H, Hlatky L, McBride WH.
    Cancer research. 2010 Nov 1;70(21):8886-95. PubMed

  37. Survival and self-renewing capacity of breast cancer initiating cells during fractionated radiation treatment.
    Lagadec C, Vlashi E, Della Donna L, Meng Y, Dekmezian C, Kim K, Pajonk F.
    Breast cancer research: BCR. 2010;12(1):R13. PubMed

  38. Real time, noninvasive imaging and quantitation of the accumulation of ligand-targeted drugs into receptor-expressing solid tumors.
    Vlashi E, Sturgis JE, Thomas M, Low PS.
    Molecular pharmaceutics. 2009 Nov-Dec;6(6):1868-75. PubMed

  39. Radiation responses of cancer stem cells.
    Vlashi E, McBride WH, Pajonk F.
    Journal of cellular biochemistry. 2009 Oct 1;108(2):339-42. PubMed

  40. In vivo imaging, tracking, and targeting of cancer stem cells.
    Vlashi E, Kim K, Lagadec C, Donna LD, McDonald JT, Eghbali M, Sayre JW, Stefani E, McBride W, Pajonk F.
    Journal of the National Cancer Institute: JNCI. 2009 Mar 4;101(5):350-9. PubMed

  41. Effects of recombinant erythropoietin on breast cancer-initiating cells.
    Phillips TM, Kim K, Vlashi E, McBride WH, Pajonk F.
    Neoplasia. 2007 Dec;9(12):1122-9. PubMed

  42. Immunomagnetic diffractometry for detection of diagnostic serum markers.
    Acharya G, Chang CL, Doorneweerd DD, Vlashi E, Henne WA, Hartmann LC, Low PS, Savran CA.
    Journal of the American Chemical Society: JACS. 2007 Dec 26;129(51):15824-9. PubMed

  43. Folate-targeted immunotherapy effectively treats established adjuvant and collagen-induced arthritis.
    Paulos CM, Varghese B, Widmer WR, Breur GJ, Vlashi E, Low PS.
    Arthritis research & therapy. 2006;8(3):R77. PubMed